05742nam 2201909z- 450 991057687430332120220621(CKB)5720000000008432(oapen)https://directory.doabooks.org/handle/20.500.12854/84569(oapen)doab84569(EXLCZ)99572000000000843220202206d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAnticancer Drugs 2021BaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (594 p.)3-0365-4348-1 3-0365-4347-3 The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure-activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.ChemistrybicsscResearch & information: generalbicssc1,2,3-triazole1,3,4-oxadiazole3-amino-4'-guanidino3,4'-bis-guanidino5-fluoruracil7-deaza-4'-thioadenosine derivativesacetamideadamantaneADC (antibody-drug conjugate)agealkylatedanticanceranticancer activityanticancer agentsapoptosisapoptosis inductionaromatase inhibitorBcl-2 inhibitorsbenzenesulfonamidesbenzimidazoleBRAFbreast cancercancercancer cell viabilitycancer vaccineCAR (chimeric antigen receptor)cardiotoxicitycarvedilolcell cycle analysischalconechalconescolony formationcombretastatin A-4concentration-guided dosingcovalent bindingCovDockcumulative dosecyclophosphamidecytotoxic activitycytotoxic agentscytotoxicitydesigned multiple liganddiphenyl etherDNA fragmentationdockingdoxazosindrug effluxdual inhibitorsdual-targeting moleculeEGFRELISAenantioselective synthesisentrectinibexportin-1gastric adenocarcinomageneric productH1299HDAC inhibitorsHER2heterocyclic compoundhistopathologyHL-60HT-29 cellshybrid compoundshybrid moleculehydrazide derivativesimidazolesImiquimodimmunotherapyin vitroin vivoindazoleIndole-based analoguesinflammationinterleukin-6intramolecular hydrogen bondisolationkidneylarotrectinibletrozoleMD simulationsMDA-MB-231 cellsmechanism predictionmiR-21mitoxantronemodel informed dosingMTT cytotoxic assayMUC1MUC16mucinmulti-kinase inhibitormultidrug resistancen/aNaMSAnitrogen scaffoldsNTRKnucleosideoxidative stresspatent reviewpemetrexedphenstatinphenyl pyridyl etherphysiologically based pharmacokineticsprotein kinase inhibitorsresin acidsolid/lipid nanoparticlessorafenibSTAT inhibitorssynthesisTDP1testisthieno[2,3-d][1,2,3]triazinethioureathymidylate synthasetissue-agnosticToll-Like ReceptortoxicityTrkTrk fusiontrypan blue assaytryptophanoltubulin polymerisation inhibitortumor spheroidstyrosil-DNA-phosphodiesterase 1urinary bladderUSFDAxanthoneChemistryResearch & information: generalMeegan Mary Jedt1325230O'Boyle Niamh MedtMeegan Mary JothO'Boyle Niamh MothBOOK9910576874303321Anticancer Drugs 20213036711UNINA